Skip to search formSkip to main contentSkip to account menu

Eylea

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
PURPOSE To investigate the effect of age on aflibercept (Eylea) response in macular edema secondary to treatment-naive diabetic… 
2019
2019
Purpose: Aflibercept (Eylea™, Regeneron) is supplied in single-use glass vials along with 1 cc polycarbonate syringes. We sought… 
2018
2018
Vascular endothelial growth factor (VEGF) is a key mediator in the development and progression of choroidal neovascularization… 
2018
2018
PurposeTo investigate the short-term effect of single intravitreal aflibercept injection on retrobulbar blood flow in patients… 
Review
2017
Review
2017
Aflibercept (Eylea®) is a fully human, recombinant fusion protein available in various countries worldwide, including those of… 
Highly Cited
2016
Highly Cited
2016
PURPOSE We determined the intraocular pharmacokinetic properties of intravitreally injected aflibercept (Eylea) in a rabbit model… 
2016
2016
Background: We present an interesting case of bilateral retinitis pigmentosa (RP)-associated cystoid macular oedema that… 
Review
2014
Review
2014
Aflibercept is a fully human, recombinant fusion protein that acts as a soluble decoy receptor for vascular endothelial growth… 
2014
2014
Purpose OPT‐302 is a soluble receptor that specifically and potently blocks VEGF‐C and VEGF‐D activity which are involved in the…